5 • 644 Ratings
🗓️ 24 November 2015
⏱️ 34 minutes
🧾️ Download transcript
In this episode, we discuss two new anti-diabetic medications: empagliflozin (Jardiance) and the EMPA-REG OUTCOME trial as well as dulaglutide (Trulicity), a new GLP1 agonist.
Click on a timestamp to play from that location
0:00.0 | Welcome to Helix Talk, a podcast presented by the Rosalind Franklin University College of Pharmacy. |
0:09.8 | We're hoping that our real-life clinical pearls and discussions will help you stay up to date |
0:15.3 | and improve your pharmacy knowledge. This podcast contains general information for educational purposes only. This is not |
0:23.1 | professional advice and should not be used in lieu of obtaining advice from a qualified health care |
0:27.8 | provider. And now, on to the show. Welcome to episode 35 of Helix Talk. I'm your co-host, Dr. Kane. |
0:35.2 | I'm Dr. Sherman. And I'm Dr. Patel. |
0:41.0 | And today we're talking about two updates regarding diabetes therapy. |
0:47.2 | And one of the update, it's not only an update to a new medication. We're talking about the same old, our friend Mpaglethosen, the brand name is Jardians. We do know there are other |
0:52.9 | two SGLT2 inhibitors out in the market to Kinnaglozine, brand name is Jardians. We do know there are other two SGLT2 inhibitors out in the market, too. |
0:56.5 | Kanaaglofosen, brand name is in Okana, and DePalphazin brand name is Farsiga. |
1:01.4 | And these were covered in detail in episode 16, but we are covering Impalphousin once again |
1:08.4 | because of the new trial and polyreg outcome trial results that were |
1:13.5 | published just very recently. And just to give background, again, episode 16 we did cover these |
1:19.8 | SGLT2 inhibitors, but essentially the way that they work is they make you urinate out more glucose. |
1:25.6 | So it decreases the threshold for when the kidney |
1:28.1 | reabs glucose. And that has some effects in terms of vital signs, some lab values, and things like that. |
1:34.8 | And then we had mentioned there was, you know, some things to be concerned about was a potential |
1:38.4 | increased risk in urinary tract infections because, again, bringing all that sugar through the |
1:43.4 | urers, and you know that that can be |
1:45.4 | problematic for outcomes so it remain to be seen how big of a problem that continues to be |
1:50.0 | and when we're thinking about urinating glucose some good things and some bad things happen |
1:54.8 | you mentioned a couple bad things some of the good things are that because you're losing calories |
... |
Please login to see the full transcript.
Disclaimer: The podcast and artwork embedded on this page are from Sean P. Kane, PharmD, BCPS, and are the property of its owner and not affiliated with or endorsed by Tapesearch.
Generated transcripts are the property of Sean P. Kane, PharmD, BCPS and are distributed freely under the Fair Use doctrine. Transcripts generated by Tapesearch are not guaranteed to be accurate.
Copyright © Tapesearch 2025.